Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSING AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN OPHTHOTECH CORPORATION AND NOVARTIS PHARMA AG MAY 19, 2014Licensing and Commercialization Agreement • August 6th, 2014 • Ophthotech Corp. • Pharmaceutical preparations • New York
This Licensing and Commercialization Agreement (“Agreement”) is made and effective as of the 19th day of May, 2014 (the “Effective Date”) by and between Ophthotech Corporation, a Delaware corporation, with offices at One Penn Plaza, 19th Floor, New York, NY 10119, U.S.A. (“Ophthotech”) and Novartis Pharma AG, a Swiss company, with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CLINICAL MANUFACTURING AND SUPPLY AGREEMENTConfidentiality Agreement • August 6th, 2014 • Ophthotech Corp. • Pharmaceutical preparations • New York
This Clinical Manufacturing and Supply Agreement (this “Agreement”) is entered into by and between AGILENT TECHNOLOGIES, INC., a Delaware corporation, having a principal office at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”) and OPHTHOTECH CORPORATION, a Delaware corporation, having a principal office at One Penn Plaza, Suite 1924, New York, NY 10119 (“Customer”) effective as of May 2, 2014 (the “Effective Date”). Agilent and Customer are each referred to herein as a “Party” and together as the “Parties”.
